Nasal Decongestants in Competitive Athletes: A Narrative Review
DOI:
https://doi.org/10.12775/QS.2026.75.74958Keywords
nasal obstruction, endurance athletes, competitive athletes, competitive sports, athletes, decongestants, nasal decongestantsAbstract
Background. Nasal obstruction is a common but often underestimated problem in endurance athletes, where breathing comfort, sleep quality, and recovery may affect training consistency and performance.
Aim. This narrative review summarizes current evidence on septal deviation, rhinitis, and chronic rhinosinusitis in endurance athletes, with emphasis on their possible impact on exercise performance.
Material and methods. PubMed and open-access sources were searched using terms related to nasal obstruction, septal deviation, rhinitis, chronic rhinosinusitis, athletes, endurance exercise, and performance. English-language full-text studies and reviews were prioritized. Athlete-specific sources were preferred, with selected clinical studies included when sports-related evidence was limited.
Results. Evidence indicates that nasal obstruction in athletes is usually multifactorial and most often linked to mucosal disease, especially rhinitis. Structural causes such as septal deviation may also be relevant. Direct evidence connecting nasal obstruction with reduced endurance performance is limited, but plausible mechanisms include increased upper airway resistance, impaired breathing comfort, altered breathing mode, poorer sleep, higher symptom burden, and reduced exercise tolerance. Symptoms may be particularly important in athletes exposed to chlorine by-products, cold dry air, seasonal allergens, and repeated high-volume ventilation.
Conclusions. Nasal obstruction should be considered a potentially modifiable factor in endurance athletes. Rhinitis is the best documented sinonasal disorder in this group, while chronic rhinosinusitis and septal deviation remain insufficiently studied. Further research is needed to determine whether treatment improves objective and subjective performance-related outcomes.
References
Baethge C, Goldbeck-Wood S, Mertens S. SANRA - a scale for the quality assessment of narrative review articles.
Res Integr Peer Rev. 2019;4:5. https://doi.org/10.1186/s41073-019-0064-8
Barroso O, Goudreault D, Carbó Banús M, Ayotte C, Mazzoni I, Boghosian T, Rabin O. Determination of urinary
concentrations of pseudoephedrine and cathine after therapeutic administration of pseudoephedrine-containing
medications to healthy subjects: implications for doping control analysis of these stimulants banned in sport.
Drug Test Anal. 2012;4(5):320-329. https://doi.org/10.1002/dta.291
Berry C, Wagner DR. Effect of pseudoephedrine on 800-m run times of female collegiate track athletes. Int J Sports
Physiol Perform. 2012;7(3):237-241. https://doi.org/10.1123/ijspp.7.3.237
Chester N, Reilly T, Mottram DR. Physiological, subjective and performance effects of pseudoephedrine and
phenylpropanolamine during endurance running exercise. Int J Sports Med. 2003;24(1):3-8.
https://doi.org/10.1055/s-2003-37195
Chester N, Mottram DR, Reilly T, Powell M. Elimination of ephedrines in urine following multiple dosing: the
consequences for athletes, in relation to doping control. Br J Clin Pharmacol. 2004;57(1):62-67.
https://doi.org/10.1046/j.1365-2125.2003.01948.x
Deckx L, De Sutter AIM, Guo L, Mir NA, van Driel ML. Nasal decongestants in monotherapy for the common cold.
Cochrane Database Syst Rev. 2016;10(10):CD009612. https://doi.org/10.1002/14651858.CD009612.pub2
Druce HM, Ramsey DL, Karnati S, Carr AN. Topical nasal decongestant oxymetazoline (0.05%) provides relief of
nasal symptoms for 12 hours. Rhinology. 2018;56(4):343-350. https://doi.org/10.4193/Rhin17.150
Dykewicz MS, Wallace DV, Amrol DJ, Baroody FM, Bernstein JA, Craig TJ, et al. Rhinitis 2020: a practice
parameter update. J Allergy Clin Immunol. 2020;146(4):721-767. https://doi.org/10.1016/j.jaci.2020.07.007
Eccles R, Eriksson M, Garreffa S, Chen SC. The nasal decongestant effect of xylometazoline in the common cold.
Am J Rhinol. 2008;22(5):491-496. https://doi.org/10.2500/ajr.2008.22.3202
Eccles R, Mårtensson K, Chen SC. Effects of intranasal xylometazoline, alone or in combination with ipratropium, in
patients with common cold. Curr Med Res Opin. 2010;26(4):889-899.
https://doi.org/10.1185/03007991003648015
European Medicines Agency. EMA confirms measures to minimise the risk of serious side effects with medicines
containing pseudoephedrine. Published January 26, 2024.
aining-pseudoephedrine [Accessed July 2, 2026].
Fowler J, Chin CJ, Massoud E, Alrajhi Y. Rhinitis medicamentosa: a nationwide survey of Canadian
otolaryngologists. J Otolaryngol Head Neck Surg. 2019;48:70. https://doi.org/10.1186/s40463-019-0392-1
Gheorghiev MD, Hosseini F, Moran J, Cooper CE. Effects of pseudoephedrine on parameters affecting exercise
performance: a meta-analysis. Sports Med Open. 2018;4:44. https://doi.org/10.1186/s40798-018-0159-7
Gill ND, Shield A, Blazevich AJ, Zhou S, Weatherby RP. Muscular and cardiorespiratory effects of pseudoephedrine
in human athletes. Br J Clin Pharmacol. 2000;50(3):205-213. https://doi.org/10.1046/j.1365-2125.2000.00252.x
Gillies H, Derman WE, Noakes TD, Smith P, Evans A, Gabriels G. Pseudoephedrine is without ergogenic effects
during prolonged exercise. J Appl Physiol (1985). 1996;81(6):2611-2617.
https://doi.org/10.1152/jappl.1996.81.6.2611
Graf P. Rhinitis medicamentosa: aspects of pathophysiology and treatment. Allergy. 1997;52(Suppl 40):28-34.
https://doi.org/10.1111/j.1398-9995.1997.tb04883.x
Grimaldi-Bensouda L, Bégaud B, Rossignol M, Avouac B, Lert F, Rouillon F, et al. Decongestant use and the risk of
myocardial infarction and stroke: a case-crossover study. Sci Rep. 2021;11:4160.
https://doi.org/10.1038/s41598-021-83718-8
Hagen M, Varbiro G, Montanari E, Ballerini Fernandes M. Revisiting rhinitis medicamentosa: examining the
evidence on topical nasal decongestants. J Pharm Pract. 2026;39(2):117-139.
https://doi.org/10.1177/08971900251350510
Hallén H, Enerdal J, Graf P. Fluticasone propionate nasal spray is more effective and has a faster onset of action than
placebo in treatment of rhinitis medicamentosa. Clin Exp Allergy. 1997;27(5):552-558.
https://doi.org/10.1111/j.1365-2222.1997.tb00744.x
Hatton RC, Winterstein AG, McKelvey RP, Shuster J, Hendeles L. Efficacy and safety of oral phenylephrine:
systematic review and meta-analysis. Ann Pharmacother. 2007;41(3):381-390.
https://doi.org/10.1345/aph.1H679
Hodges K, Hancock S, Currell K, Hamilton B, Jeukendrup AE. Pseudoephedrine enhances performance in 1500-m
runners. Med Sci Sports Exerc. 2006;38(2):329-333. https://doi.org/10.1249/01.mss.0000183201.79330.9c
Hox V, Beyaert S, Bullens D, Couto M, Langer D, Hellings PW, et al. Tackling nasal symptoms in athletes: moving
towards personalized medicine. Allergy. 2021;76(9):2716-2729. https://doi.org/10.1111/all.14786
Jolley D, Dawson B, Maloney S, White J, Goodman C, Peeling P. Hydration and urinary pseudoephedrine levels
after a simulated team game. Int J Sport Nutr Exerc Metab. 2014;24(3):325-332.
https://doi.org/10.1123/ijsnem.2013-0076
Kasterka N, Kolasa M, Karbownik L, Figwer A, Figwer K, Dzitkowska K, et al. Exercise-induced laryngeal
obstruction in athletes with exertional dyspnoea: a narrative review of diagnostic challenges, management and
sport participation. Qual Sport. 2026;59:72749. https://doi.org/10.12775/QS.2026.59.72749
Matyja M, Kowalska M, Mazur A, Brodziak J, Fojcik K, Ciszewska W, et al. Rhinitis in swimmers: a clinical issue at
the intersection of sports medicine and otorhinolaryngology. Qual Sport. 2025;47:66927.
https://doi.org/10.12775/QS.2025.47.66927
McIntosh C, Clemm HH, Sewry N, Hrubos-Strøm H, Schwellnus MP. Diagnosis and management of nasal
obstruction in the athlete: a narrative review by subgroup B of the IOC Consensus Group on Acute Respiratory
Illness in the Athlete. J Sports Med Phys Fitness. 2021;61(8):1144-1158.
https://doi.org/10.23736/S0022-4707.21.12821-X
Medicines and Healthcare products Regulatory Agency. Nasal decongestant sprays and drops containing
xylometazoline hydrochloride/oxymetazoline hydrochloride: increased risk of rebound congestion, rhinitis
medicamentosa and tachyphylaxis with overuse. Drug Safety Update. Published April 30, 2026.
hloride-slash-oxymetazoline-hydrochloride-increased-risk-of-rebound-congestion-rhinitis-medicamentosa-and-t
achyphylaxis-with-overuse [Accessed July 2, 2026].
Neighbors CL, Fernandez Salvador C, Zhu B, Camacho M, Tsai P. Intranasal corticosteroid and oxymetazoline for
chronic rhinitis: a systematic review. J Laryngol Otol. 2022;136(1):8-16.
https://doi.org/10.1017/S0022215121003364
Pietrucha T, Gołdyn M, Kubala K, Grabińska M, Halik P, Jusiak J. Subcutaneous versus sublingual allergen
immunotherapy in allergic rhinitis and asthma: a comparative narrative review. Qual Sport. 2026;51:68476.
https://doi.org/10.12775/QS.2026.51.68476
Pokrywka A, Kwiatkowska D, Gorczyca D. Problems of the use of pseudoephedrine by athletes. Int J Sports Med.
2009;30(8):569-572. https://doi.org/10.1055/s-0029-1202826
Price OJ, Walsted ES, Bonini M, Brannan JD, Bougault V, Carlsen KH, et al. Diagnosis and management of allergy
and respiratory disorders in sport: an EAACI task force position paper. Allergy. 2022;77(10):2909-2923.
https://doi.org/10.1111/all.15431
Pritchard-Peschek KR, Jenkins DG, Osborne MA, Slater GJ. Pseudoephedrine ingestion and cycling time-trial
performance. Int J Sport Nutr Exerc Metab. 2010;20(2):132-138. https://doi.org/10.1123/ijsnem.20.2.132
Pritchard-Peschek KR, Jenkins DG, Osborne MA, Slater GJ, Taaffe DR. The dose-response relationship between
pseudoephedrine ingestion and exercise performance. J Sci Med Sport. 2014;17(5):531-534.
https://doi.org/10.1016/j.jsams.2013.07.015
Roberts WO, Armstrong LE, Sawka MN, Yeargin SW, Heled Y, O'Connor FG. ACSM Expert Consensus Statement
on Exertional Heat Illness: Recognition, Management, and Return to Activity. Curr Sports Med Rep.
2023;22(4):134-149. https://doi.org/10.1249/JSR.0000000000001058
Salerno SM, Jackson JL, Berbano EP. Effect of oral pseudoephedrine on blood pressure and heart rate: a
meta-analysis. Arch Intern Med. 2005;165(15):1686-1694. https://doi.org/10.1001/archinte.165.15.1686
Stinson RJ, Sadofsky LR. Part 1 - imidazolines and the changing face of nasal decongestants. Front Pharmacol.
2025a;16:1655252. https://doi.org/10.3389/fphar.2025.1655252
Stinson RJ, Sadofsky LR. Part II - imidazolines and rhinitis medicamentosa: how can we tackle the rebound
dilemma? Front Pharmacol. 2025b;16:1655254. https://doi.org/10.3389/fphar.2025.1655254
Surda P, Walker A, Putala M, Siarnik P. Prevalence of rhinitis in athletes: systematic review. Int J Otolaryngol.
2017;2017:8098426. https://doi.org/10.1155/2017/8098426
Thongngarm T, Assanasen P, Pradubpongsa P, Tantilipikorn P. The effectiveness of oxymetazoline plus intranasal
steroid in the treatment of chronic rhinitis: a randomized controlled trial. Asian Pac J Allergy Immunol.
2016;34(1):30-37.
Trinh KV, Kim J, Ritsma A, Kim K. Effect of pseudoephedrine in sport: a systematic review. BMJ Open Sport Exerc
Med. 2015;1(1):e000066. https://doi.org/10.1136/bmjsem-2015-000066
U.S. Food and Drug Administration. Proposed Administrative Order OTC000036: Amending Over-the-Counter
Monograph M012, Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for
Over-the-Counter Human Use. Published November 7, 2024.
https://www.accessdata.fda.gov/scripts/cder/omuf/index.cfm?event=OrderDetail&orderid=OTC000036
[Accessed July 2, 2026].
Watanabe H, Foo TH, Djazaeri B, Duncombe P, Mackay IS, Durham SR. Oxymetazoline nasal spray three times
daily for four weeks in normal subjects is not associated with rebound congestion or tachyphylaxis. Rhinology.
2003;41(3):167-174.
World Anti-Doping Agency. TUE Physician Guidelines: Sinusitis/Rhinosinusitis. Version 2.0. November 2021a.
inal_november_2021.pdf [Accessed July 2, 2026].
World Anti-Doping Agency. World Anti-Doping Code. 2021b.
https://www.wada-ama.org/sites/default/files/resources/files/2021_wada_code.pdf [Accessed July 2, 2026].
World Anti-Doping Agency. International Standard: Prohibited List 2026. Effective January 1, 2026.
https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf [Accessed
July 2, 2026].
Yang X, Eremeeva K, Svistushkin V, Lisenkova D, Smolyarchuk E, Nedorubov A. Variants of rhinitis
medicamentosa treatment: a systematic review. Eur Arch Otorhinolaryngol. 2025;282:4407-4416.
https://doi.org/10.1007/s00405-025-09344-6
Zucker SM, Barton BM, McCoul ED. Management of rhinitis medicamentosa: a systematic review. Otolaryngol
Head Neck Surg. 2019;160(3):429-438. https://doi.org/10.1177/0194599818807891
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Bartosz Minik, Kamila Ryń, Karolina Cieślewicz, Kinga Szymańska-Zdyb, Patrycja Nowaczek, Krzysztof Mirkowski, Barbara Braksal, Zuzanna Wanda Szurek, Zofia Chyła, Adam Miroński

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 19
Number of citations: 0